Uniphar (ISE:UPR) Stock Can Revenue Growth Outrun Cash Flow Strain?

Uniphar walked into these results with a stock that has slipped roughly 14% over the past three months, and another small step down over the past week. That tells you sentiment was already fragile. Then H1 landed with a different story. Gross profit reached €236.5m and EBITDA came in at €61.1m, with adjusted earnings per share at €0.109. The key plot twist is not revenue. It is the pressure on profitability and free cash flow that collides with a healthcare distributor now heavily funding its future infrastructure.

Is Uniphar a rare bargain at a €4.13 share price, or are the 1.7% net margin and weak debt coverage exactly what the market is pricing in? Compare that tension against our valuation analysis for Uniphar

H1 2026 Earnings Summary

• Revenue (H1 2026 vs. H1 2025): €1,591.855m vs. €1,485.492m (up about 7.2%)
• Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): €19.993m vs. €17.473m (up about 14.4%)
• Basic EPS (H1 2026 vs. H1 2025): €0.077 vs. €0.066159 (up about 16.4%)
• Trailing Net Profit Margin (Last 12 Months vs. Prior Year): 1.7% vs. 2.3% (margin compressed)

Prefer clean charts instead of another dense block of financial figures? See Uniphar’s full picture, including how its earnings power lines up against its current share price, in our visual company report for Uniphar.

Uniphar’s growth thesis meets real operating proof

Bulls argue Uniphar can turn its specialty focus and heavy infrastructure build into a higher margin, compounding platform. H1 gives that story some grounding. Group gross profit grew faster than EBITDA, yet adjusted EPS rose 11.2%, which points to improving efficiency rather than just buying growth. Pharma and Medtech together delivered mid to high single digit organic gross profit gains, with Medtech EBITDA of €24.1m at roughly 15.9% margin. That supports the claim that higher value services and geographic expansion are beginning to scale. Supply Chain & Retail still runs on thin margin at about 2.1% but remains cash generative before heavy capex. Management kept the €200m EBITDA ambition for 2028 and reiterated a 60% to 70% long term free cash flow conversion target, which signals that current spending is tied to a defined earnings framework rather than open ended expansion.

Bear case on cash strain and execution gets airtime

The main bearish story around Uniphar focuses on weak cash generation, stretched capex and project execution risk. H1 does not dismiss that concern. Free cash flow conversion fell to about 77% in the wrong direction, with reported free cash flow at a €47m outflow and leverage at 2.4x net bank debt to EBITDA, close to management’s ceiling. Strategic capex reached €36.6m in six months and another €20m is earmarked just to get the Irish distribution centre live, with initial facility utilisation described at only about 30%. The delay of the Greenogue 2 go live into February 2027 lowers operational risk but extends the period of dual running and one off costs. Recent share performance, down roughly 14% over 90 days, lines up with a market that is already discounting these near term pressure points.

After a €47m free cash outflow, 2.4x net debt to EBITDA and significant spending on a half-utilised hub, it is fair to ask whether Uniphar’s funding gap is a short-term growing pain or a structural drag. Scan our risk analysis for Uniphar which shows 1 important warning sign

Stay Ahead Of Your Next Move

If Uniphar’s mix of slim margins, heavy infrastructure spend and fragile sentiment has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch for a better entry point. After you build a position, use the Portfolio Command Center to cut through noise and focus on the updates that matter for your holdings. For longer term context and fresh angles, tap into thousands of shared views through the Community. Spot potential catalysts and pressure points early so you can react faster and stay ahead of the wider market.

Seeking Alternatives Beyond Uniphar?

Fresh ideas often move first. By the time a breakout story hits headlines, early entries may already have moved significantly. Consider scanning these under-the-radar choices before any potential momentum is widely recognized.

• Focus on companies with cash rich balance sheets and steadier momentum with a curated list of solid balance sheet and fundamentals stocks (194 results) before others notice the strength behind these quieter compounders.
• Monitor early capital rotation into potential next wave infrastructure by reviewing 39 power grid technology and infrastructure stocks while these grid enablers may still be priced as overlooked utilities rather than established growth stories.
• Look for income that continues to work even when prices fluctuate by scanning 140 dividend fortresses, which is built around resilient cash flows and yields that could reward patience.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com